Sankyo Co., Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| 6417.T | 1655.HK | 8400.HK | 6460.T | N9B.F | 7458.T | |
|---|---|---|---|---|---|---|
| Market cap | 429.49B | 105.84M | 77.00M | 686.62B | 25.31B | 185.25B |
| P/E (TTM) | 11.3 | 1.1 | 7.7 | 250.3 | 29.0 | 11.2 |
| Forward P/E | 1,449.7 | — | — | 13.7 | 0.1 | 12.5 |
| Price/book | 1.6 | 0.2 | 2.7 | 1.9 | 4.8 | 1.4 |
| Dividend yield | 4.60% | — | — | 1.56% | 0.64% | 3.74% |
| 1-year change | −16.92% | −38.24% | +122.22% | +31.72% | +70.58% | +10.31% |
| Today | −2.09% | −2.00% | −3.75% | −3.78% | −5.28% | −1.48% |
The closest companies by business and industry (Gambling). Prices may be delayed up to 20 min.
Latest news
All 6417.T news ›Daiichi Sankyo: Rising Oncology Pureplay Investment At Tantalizing Value
Japan Another Mountain's Rock Investing Summary I continue to rate Daiichi Sankyo a buy for risk-tolerant, long-term investors following a 43% share-price decline despite DXd’s progress. Enhertu generated $4.98 billion in FY2025 sales,…
Daiichi Sankyo Terminates Early Cancer Trial DS-9606a: What Investors Should Know
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer. Tipranks - Sat Mar 21, 11:34AM CDT Daiichi Sankyo Company…
FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor
-- A rare, potentially destructive tumor of the joint or tendon sheath, tenosynovial giant cell tumor (TGCT) can lead to significant pain, joint destruction, frequent surgery and loss of mobility -- No FDA-approved systemic therapy…
AstraZeneca, Daiichi Sankyo win EU adjuvant approval for Enhertu in HER2-positive early breast cancer
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer. Tipranks - Wed Oct 28, 3:12AM CDT AstraZeneca ( (GB:AZN) ) has…
Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Stock Short Interest Drops 88.8%
Posted by Sarita Garza on Nov 13th, 2026 Share on Twitter Share on Facebook Share on LinkedIn Share on Stocktwits Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) saw a large
Sankyo Keizai Shimbun | Upper House Election: National Party Makes Major Leap to 125 Seats, Exceeding Forecasts; Combined with Patriotic Alliance, They Secure a Majority of 143 Seats; A Blow to the Miyazawa Administration
National Party leaps from 28 to 84 seats in contested races, surpassing the Conservative Party to become the largest party in the Upper House National and Patriotic parties cross the majority threshold; with the Democratic Reform Union,…
IDEL, Daiichi Sankyo Team Up To Test Multi-Drug Conjugate For Solid Tumors
iDEL Therapeutics said Monday it entered multi-year global research collaboration with Daiichi Sankyo Company, Ltd. (DSNKY) to evaluate a multi-drug conjugate for selected solid tumors. Researchers at iDEL and the Daiichi Sankyo Research…
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
/PRNewswire/ - Daiichi Sankyo (TSE: 4568) has further established its presence in Canada with the official opening of its permanent headquarters in Toronto,... - Investment in Canadian headquarters fuels expansion of Canadian operations,…
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
BASKING RIDGE, N.J. and TOKYO, Aug. 31, 2017 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced positive top-line results from REDUCER (an Asian, phase 3, ... BASKING RIDGE, N.J. and TOKYO, Aug. 31,…
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit …
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics … Source:…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com9
- seekingalpha.com4
- theglobeandmail.com2
- themarketsdaily.com2
- longevity.technology1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.